Microbix to spin off Urokinase into newly formed Klarogen Biotherapeutics
Klarogen to acquire all remaining Urokinase inventory, sales and marketing infrastructure and NDA from ImaRx upon completion of financing
Microbix intends to transfer to Klarogen Biotherapeutics Inc., its Urokinase manufacturing facilities and equipment, worldwide commercial rights to all Urokinase therapeutic indications, and the associated staff and management.
Under the terms of a newly arranged letter of intent, Klarogen would purchase the Urokinase assets of ImaRx Therapeutics, Inc. of Tuscon, Arizona, for $17 million. These assets would include ImaRx' remaining Urokinase inventory, the NDA (formerly known as Abbokinase(R), now known as Kinlytic (TM)) and the sales and marketing infrastructure. The Boards of Directors of both companies have approved a letter of intent to this effect.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.